ASML Rides Two Waves: Terafab Euphoria and the Cost of Being the Industry's Bottleneck

ASML shares surge 52% in 2025, trading 40% above 200-day average, driven by AI capacity crunch, Elon Musk’s $55B Terafab plan, and JPMorgan’s €1,900 target, though TSMC delays high-NA EUV adoption.

The Dutch lithography giant has become the stage for a peculiar tug-of-war. On one side sits the tangible reality of an AI-driven capacity crunch that has left chipmakers scrambling for every EUV machine ASML can produce. On the other, a speculative jolt from Elon Musk’s vision of a $55 billion “Terafab” megaproject — enough to send the stock to a fresh all-time high of €1,580.60 on Tuesday before profit-taking pulled it back to the €1,500–€1,502 zone.

That high-water mark, just days old, puts the shares roughly 5% above last week’s close near €1,502.60 — itself only a whisker under the previous record. The longer-run trajectory is even starker: the stock has surged 52% since January and 120% over twelve months, with a 16% monthly sprint that has all but erased lingering doubts.

A 40% gap over the 200-day line

Technical analysis underscores the extent of the rally. ASML now trades almost 40% above its 200-day moving average. Such a gap is not a sign of a broken chart, but it raises a pointed question: can the underlying fundamentals grow fast enough to validate such altitude? The stock’s valuation already embeds a nearly perfect scenario of persistent scarcity — what the market is effectively pricing is not the discovery of a bottleneck, but its frictionless resolution.

The strategic argument for ASML remains structural. Management has tethered the industry’s brighter growth outlook directly to AI investment, with customers demanding new systems while simultaneously upgrading existing installed bases. The chief executive recently described the semiconductor market as “extremely tight,” with demand outstripping production capacity across the supply chain. ASML is working hard to boost its own productivity, acutely aware that it cannot afford to become the bottleneck that slows down the entire sector.

Wall Street’s upgraded targets

The Terafab project, a joint venture between Tesla and SpaceX, would require cutting-edge extreme ultraviolet lithography for high-volume chip fabrication in Texas. Since ASML is the world’s sole supplier of those machines, the potential order pipeline has caught the attention of major banks. JPMorgan now sees ASML capable of delivering more than 110 low-NA EUV systems annually without expanding its existing factories — well above the prior market assumption of 90 units. The bank set a price target of €1,900, while Bank of America went even higher, to €1,921.

Yet the market’s enthusiasm is tempered by a notable counterweight. Taiwan Semiconductor Manufacturing, ASML’s largest customer, has decided to postpone the adoption of the newest high-NA EUV tools for mass production until 2029, citing the prohibitive cost of roughly €350 million per machine. For the next chip generation, TSMC considers current technology sufficient. That delay adds a layer of tension to the “perfect execution” narrative that investors have baked into the stock.

Perfection demanded daily

The company’s market capitalisation stands at around €584 billion (roughly $674 billion), reflecting a premium that leaves little room for stumbles. ASML is no longer being judged on whether AI matters — that is taken as given. The scrutiny now falls on how efficiently the company monetises the logjam. Delayed deliveries or hesitant customers would not be forgiven easily.

The recent minor pullback after the record high caused no panic; it was merely a pause following a massive rally. The stock remains comfortably above its 100-day moving average of around €1,247, a level that signals confidence rather than caution. But for ASML, the scarcity premium is real and must be re-earned each day at these heights. The Terafab dream and the AI bottleneck are two powerful engines — but they also raise the bar for flawless execution to an exacting standard.